COMP <GO>
INFU vs UNH // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
InfuSystems Holdings Inc. (NYSE) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: INFU 6
— UNH 7
■ METRIC PARITY
LAST: $14.45 (+0.91%) • MKT CAP: $287.8M
options-implied-move
—
LAST: $410.91 (+0.94%) • MKT CAP: $368.83B
options-implied-move
6.74%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INFU VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INFU | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 56.00% | 88.57% | -32.57 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 12.80% | 11.47% | +1.33 | INFU | /roic <GO> |
| EV/EBITDA & P/E Valuation | 24.5x | 16.4x | +8.05 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 8.29% | 6.48% | +1.81 | INFU | /fcf-yield <GO> |
| Operating Margin | 8.30% | 4.82% | +3.48 | INFU | /operating-margins <GO> |
| Net Profit Margin | 4.60% | 3.14% | +1.46 | INFU | /net-margins <GO> |
| Revenue Growth (YoY) | 6.40% | 6.46% | -0.06 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.16 | 3.12 | +2.04 | INFU | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | INFU | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 58.6 | 59.2 | -0.62 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 40.4x | 17.1x | +23.31 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $287.8M | $368.83B | -$368.54B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INFU REV | UNH REV | INFU GROSS % | UNH GROSS % | INFU FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $143.4M | $447.57B | 56.0% | 88.7% | $23.8M | $16.07B |
| FY 2024 | $134.9M | $400.28B | 52.2% | 88.3% | $19.4M | $20.70B |
| FY 2023 | $125.8M | $371.62B | — | 89.6% | $11.2M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INFU // BETA —
UNH // BETA 0.33